CytomX Therapeutics Management
Management criteria checks 4/4
CytomX Therapeutics' CEO is Sean McCarthy, appointed in Aug 2011, has a tenure of 14.58 years. total yearly compensation is $1.75M, comprised of 38.5% salary and 61.5% bonuses, including company stock and options. directly owns 0.27% of the company’s shares, worth $2.64M. The average tenure of the management team and the board of directors is 3.2 years and 6.2 years respectively.
Key information
Sean McCarthy
Chief executive officer
US$1.8m
Total compensation
| CEO salary percentage | 38.53% |
| CEO tenure | 14.6yrs |
| CEO ownership | 0.3% |
| Management average tenure | 3.2yrs |
| Board average tenure | 6.2yrs |
Recent management updates
Recent updates
CytomX: The Probody Mask Just Slipped, And Investors Like What They See (Upgrade)
Mar 16What CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) 35% Share Price Gain Is Not Telling You
Jan 28
Analysts Just Shaved Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Forecasts Dramatically
Nov 13CytomX Therapeutics, Inc. (NASDAQ:CTMX) Soars 66% But It's A Story Of Risk Vs Reward
Oct 18Not Many Are Piling Into CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock Yet As It Plummets 26%
Aug 14Here's Why We Think CytomX Therapeutics (NASDAQ:CTMX) Is Well Worth Watching
Jun 18CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Leap 225% Yet They're Still Not Telling The Full Story
May 20CytomX Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
May 16Revenues Working Against CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Share Price Following 26% Dive
Apr 05
Advancements In CX-904 And CX-2051 May Drive Future Revenue Amid Funding Uncertainties
Multiple clinical readouts in 2025 could boost shareholder value and future revenue via new drug approvals.CytomX Therapeutics, Inc. (NASDAQ:CTMX) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Feb 04CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Bounce 26% But Its Business Still Trails The Industry
Dec 17Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues
Oct 26CytomX Therapeutics' Probody Platform: Potential And Pitfalls In Oncology Treatments
Jul 15The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%
Jun 15We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now
May 09CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling
May 02CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%
Apr 27CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town
Apr 25CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | -US$20m |
| Sep 30 2025 | n/a | n/a | US$28m |
| Jun 30 2025 | n/a | n/a | US$48m |
| Mar 31 2025 | n/a | n/a | US$42m |
| Dec 31 2024 | US$2m | US$675k | US$32m |
| Sep 30 2024 | n/a | n/a | US$14m |
| Jun 30 2024 | n/a | n/a | US$11m |
| Mar 31 2024 | n/a | n/a | US$17m |
| Dec 31 2023 | US$3m | US$652k | -US$569k |
| Sep 30 2023 | n/a | n/a | -US$10m |
| Jun 30 2023 | n/a | n/a | -US$42m |
| Mar 31 2023 | n/a | n/a | -US$71m |
| Dec 31 2022 | US$3m | US$623k | -US$99m |
| Sep 30 2022 | n/a | n/a | -US$149m |
| Jun 30 2022 | n/a | n/a | -US$143m |
| Mar 31 2022 | n/a | n/a | -US$132m |
| Dec 31 2021 | US$4m | US$616k | -US$116m |
| Sep 30 2021 | n/a | n/a | -US$72m |
| Jun 30 2021 | n/a | n/a | -US$64m |
| Mar 31 2021 | n/a | n/a | -US$61m |
| Dec 31 2020 | US$3m | US$595k | -US$65m |
| Sep 30 2020 | n/a | n/a | -US$54m |
| Jun 30 2020 | n/a | n/a | -US$63m |
| Mar 31 2020 | n/a | n/a | -US$76m |
| Dec 31 2019 | US$4m | US$575k | -US$133m |
Compensation vs Market: Sean's total compensation ($USD1.75M) is below average for companies of similar size in the US market ($USD3.57M).
Compensation vs Earnings: Sean's compensation has been consistent with company performance over the past year.
CEO
Sean McCarthy (58 yo)
Dr. Sean A. McCarthy, D.Phil., served as an Independent Director at OncoResponse, Inc. since August 2021 until October 2025. He has been the Chief Executive Officer of CytomX Therapeutics, Inc. since Augus...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 14.6yrs | US$1.75m | 0.27% $ 2.6m | |
| SVP & Chief Financial Officer | 3.5yrs | US$914.28k | 0.035% $ 339.5k | |
| Chief Medical Officer | 2.7yrs | US$808.35k | 0.0022% $ 21.1k | |
| Senior VP & Chief Scientific Officer | 3.2yrs | US$1.21m | 0.052% $ 504.2k | |
| Senior VP | 7.8yrs | US$1.21m | 0.042% $ 400.4k | |
| Senior VP & Chief Human Resources Officer | no data | no data | no data | |
| Senior Vice President of Intellectual Property | 7.1yrs | no data | no data | |
| Senior Vice President of Quality & Product Manufacturing | 3.2yrs | no data | no data | |
| Senior Vice President of Alliances & Program Leadership | 1yr | no data | no data | |
| Chief Business Officer & Senior VP | less than a year | no data | no data |
Experienced Management: CTMX's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 14.6yrs | US$1.75m | 0.27% $ 2.6m | |
| Independent Director | 6.8yrs | US$108.73k | 0.0024% $ 22.9k | |
| Member of Scientific Advisory Board | 6.2yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5.3yrs | US$112.23k | 0% $ 0 | |
| Independent Director | 7.3yrs | US$110.73k | 0% $ 0 | |
| Lead Independent Director | 10.5yrs | US$138.73k | 0% $ 0 | |
| Independent Director | 5.9yrs | US$114.23k | 0% $ 0 | |
| Member of Scientific Advisory Board | 5.3yrs | US$8.03m | no data | |
| Independent Director | 4.5yrs | US$102.73k | 0% $ 0 | |
| Member of Scientific Advisory Board | 6.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.2yrs | no data | no data |
Experienced Board: CTMX's board of directors are considered experienced (6.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/22 08:23 |
| End of Day Share Price | 2026/03/20 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CytomX Therapeutics, Inc. is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Etzer Darout | Barclays |
| Ying Huang | BofA Global Research |